Breaking News, Financial News

Financial Report: Elan

Records $12.1 million in Tysabri royalties in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Elan   3Q Revenues: $48.6 million (n/a) 3Q Loss: $13.8 million (loss of $229.9 million 3Q12) YTD Revenues: $105.1 million (n/a) YTD Earnings: $2.3 billion (loss of $290.2 million) Comments: Following the transfer of Tysabri rights to partner Biogen, Elan receives royalties on Tysabri in-market sales.The company recorded $12.1 million in the quarter, reflecting the first full quarter of the new royalty arrangements on Tysabri. Shareholder meetings in November will address the progression of t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters